Education

1) 9/2000-7/2005, Graduate student, Institute of Medicinal Plant, Peking Union Medical College; Major: Pharmacology, Academic Degree: Ph.D

2) 9/1993-7/1997, Undergraduate Student, Department of Pharmaceutical Sciences, Hunan University of Traditional Chinese Medicine; Major: Pharmaceutics, Academic Degree: BS

Professional Experience

1) 12/2012-present, Associate professor of pharmacology, Graduate School at Shenzhen, Tsinghua University, China

2) 12/2014-12/2015, Visiting Scholar, Pathology and Laboratory Medicine, Perelman Medical School, University of Pennsylvania, PA, USA

3) 6/2013-8/2013, Short-term visiting scholar, Bioengineering, Lehigh University, PA, USA

4) 7/2007-11/2012, Lecturer of pharmacology, Graduate School at Shenzhen, Tsinghua University

5) 7/2005-6/2007, Postdoctoral fellow of biology, Graduate School at Shenzhen, Tsinghua University

6) 9/1997-7/2000, Assistant tutor of pharmacology, Yiyang Health School, Yiyang, Hunan

Additional Positions

Editor board member of Molecules; editor board member of Chinese Journal of Integrative medicine

Opening

Member of editorial board of China Journal of Chinese Materia Medica

Personal Webpage

Pharmacological research in the fields of diabetes, hyperlipidemia, and obesity.

Current Courses

Pharmacogenetics and Toxicology

Pharmacology and pharmacology experimental technology

Medical and biological experiments （Rotation 4）

Bioethics and scientific ethics

Research Interests

Pharmacological research in the fields of diabetes, hyperlipidemia, and obesity.

Selected Publications

[1]Yangyang Wang#, Yipei Ding#,Pengbo Sun#, Wanqiu Zhang#, Qilei Xin, Ningchao Wang, Yaoyun Niu, Yang Chen, Jingyi Luo, Jinghua Lu, Jin Zhou, Naihan Xu, Yaou Zhang, Weidong Xie*. Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2/AMPK Pathway. Antioxidants 2022, 11(5), 799.

[2]Liao W#, Xu N#, Zhang H, Liao W, Wang Y, Wang S, Zhang S, Jiang Y, Xie W*, Zhang Y*. Persistent high glucose induced EPB41L4A-AS1 inhibits glucose uptake via GCN5 mediating crotonylation and acetylation of histones and non-histones. Clinical and Translational Medicine. 2022 Feb;12(2): e699.

[3]Yaoyun Niu#, Yuehui Zhang#, Yang Chen, Wanqiu Zhang, Wenhui Hao, Jinghua Lu, Jin Zhou, Lijun Wang, Weidong Xie*. Canagliflozin ameliorates NLRP3 inflammasome-mediated inflammation through inhibiting NF-κB signaling and upregulating Bif-1. Frontiers in Pharmacology. 2022 Mar 28; 13:820541.

[4]Luo J, Sun P, Zhang X, Lin G, Xin Q, Niu Y, Chen Y, Xu N, Zhang Y, Xie W*. Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway. International Journal of Molecular Sciences. 2021 Dec 11;22(24):13336.

[5]Luo J, Sun P, Wang Y, Chen Y, Niu Y, Ding Y, Xu N, Zhang Y, Xie W*. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. European Journal of Pharmacology. 2021 Jul 3; 907:174304.

[6]Pengbo Sun#, Yangyang Wang#, Yipei Ding, Jingyi Luo, Jin Zhong, Naihan Xu, Yaou Zhang, Weidong Xie*. Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic hearts by inhibiting the mTOR/HIF-1α pathway. iScience. 2021 May 7;24(6):102521.

[7]Yaoyun Niu#, Yang Chen#, Pengbo Sun, Yangyang Wang, Jingyi Luo, Yipei Ding, Weidong Xie*. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: a potential COVID-19 treatment. International Immunopharmacology. 2021 Jul; 96:107773.

[8]Zhong J#, Sun P#, Xu N, Liao M, Xu C, Ding Y, Cai J, Zhang Y*, Xie W*. Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin. Biochemical Pharmacology. 2020 May; 175:113856.

[9]Zhao Y#, Wang Z#, Mao Y, Li B, Zhu Y, Zhang S, Wang S, Jiang Y, Xu N, Xie Y, Xie W*, Zhang Y*. NEAT1 regulates microtubule stabilization via FZD3/GSK3β/P-tau pathway in SH-SY5Y cells and APP/PS1 mice. Aging (Albany NY). 2020 Nov 18;12(22):23233-23250.

[10]Lee M, Zhao H, Liu X, Liu D, Chen J, Li Z, Chu S, Kou X, Liao S, Deng Y, Li H*, Xie W*. Protective Effect of Hydroxysafflor Yellow A on Nephropathy by Attenuating Oxidative Stress and Inhibiting Apoptosis in Induced Type 2 Diabetes in Rat. Oxidative Medicine and Cellular Longevity. 2020 Mar 11; 2020:7805393.

[11]Xu C#, Wang W#, Zhong J, Lei F, Xu N, Zhang Y, Xie W*. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochemical Pharmacology. 2018 Mar 15; 152:45-59

[12]Liao M, Liu Q, Li B, Liao W, Xie W*, Zhang Y*. A group of long noncoding RNAs identified by data mining can predict the prognosis of lung adenocarcinoma. Cancer Science. 2018 Dec;109(12):4033-4044.

[13]Wan G#, Xie W#, Liu Z, Xu W, Lao Y, Huang N, Cui K, Liao M, He J, Jiang Y, Yang BB, Xu H, Xu N, Zhang Y. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy. 2014;10(1):70-9.

[14]Xie Weidong, Zhao Yunan, Du Lijun*. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. Journal of Ethnopharmacology 2012;140(2):345-67.

[15]Weidong Xie, Lijun Du*. Diabetes is an inflammatory disease: evidences from traditional Chinese Medicines. Diabetes, Obesity and Metabolism 2011; 13:289-301.

Books

1)9/2000-7/2005, Graduate student, Institute of Medicinal Plant, Peking Union Medical College; Major: Pharmacology, Academic Degree: Ph.D

2)9/1993-7/1997, Undergraduate Student, Department of Pharmaceutical Sciences, Hunan University of Traditional Chinese Medicine; Major: Pharmaceutics, Academic Degree: BS

Patents

1)12/2012-present, Associate professor of pharmacology, Graduate School at Shenzhen, Tsinghua University, China

2)12/2014-12/2015, Visiting Scholar, Pathology and Laboratory Medicine, Perelman Medical School, University of Pennsylvania, PA, USA

3)6/2013-8/2013, Short-term visiting scholar, Bioengineering, Lehigh University, PA, USA

4)7/2007-11/2012, Lecturer of pharmacology, Graduate School at Shenzhen, Tsinghua University

5)7/2005-6/2007, Postdoctoral fellow of biology, Graduate School at Shenzhen, Tsinghua University

6)9/1997-7/2000, Assistant tutor of pharmacology, Yiyang Health School, Yiyang, Hunan